|Dr. Xiaoxin "Luke" Chen|
Published: Thursday, September 20, 2012
AbD Serotec, a division of MorphoSys AG, has donated more than 500 catalog antibodies to North Carolina Central University cancer researcher and Associate Professor Xiaoxin “Luke” Chen. Dr. Chen said that the research reagents would be distributed for use across five labs researching four different cancers — oro-esophageal, prostate, breast and pancreatic cancer — at NCCU’s Julius L. Chambers Biomedical/Biotechnology Research Institute (BBRI).
The scientists use the antibodies to test for the presence or absence of particular cancer genes that characterize cancer development. “Using these antibodies as tools,” Chen said, “we can detect cancer genes, and further understand how these genes work together to turn normal cells into cancer cells and make cancer cells more aggressive.”
George Wohlford, general manager – Americas for AbD Serotec, said, “As a global supplier of antibodies to the commercial and research communities, AbD Serotec believes we should support academic research whenever possible. This donation should benefit NCCU and Dr. Chen as they continue to execute critical cancer research that will hopefully produce beneficial results. We are also pleased, as a Raleigh-based business, that we are able to have a positive impact on local academic research.”
Chen said he and his NCCU colleagues are pleased to receive this material. “AbD Serotec has been in the business of producing high-quality antibodies for many years. This donation is a big help to our continuing studies on cancer.”